{"id":516432,"date":"2021-07-22T08:33:38","date_gmt":"2021-07-22T12:33:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/"},"modified":"2021-07-22T08:33:38","modified_gmt":"2021-07-22T12:33:38","slug":"rubius-therapeutics-to-announce-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/","title":{"rendered":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., July  22, 2021  (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc.\u00a0(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122 for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on\u00a0Monday, August 9, 2021, before market open.<\/p>\n<p>The company will not be hosting a teleconference in conjunction with its financial results press release.<\/p>\n<p>\n        <strong>About Rubius Therapeutics<\/strong><br \/>\n        <br \/>Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary RED PLATFORM\u00ae was designed to genetically engineer and culture Red Cell Therapeutics\u2122 that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius\u2019 initial focus is to advance RCT\u2122 product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities \u2014 potent cell-cell interaction and tolerance induction. Rubius\u00a0Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named\u00a02021\u00a0Best Places to Work in Rhode Island\u00a0by Providence Business News. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WYQ05xN-w9eupr9qk2JsfRwv5b54o8eVwDRMe2mwQGFII0jj6k6TgC0MFvKALnGIV-pzLUHiGFJMYjn4P2cmtQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.rubiustx.com<\/a>, follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JMZQHsPRJJaqYcL9qxuMaIIkXDWSVUPq2QXzzIxjjPbGOmwaOu_rxrBo503dpno6yBC68PmSikyoVKLL51Y2Iw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rQHtcJ77WlIgGdxPLYX6DeOZ4ljzM9lrunK5dklFlvVp-z5KNGxEENWFItR2jW9UKj9TsF4CkRT4zyYNGfsMJjj0qlFO8rOMJTc1u8zpX62TNkCYvb-2IEWayUqB6KVt\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> or like us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ggUztLtmxS621ikVDtR6-bWvH3j8JWim8w1tnEi2luwZP7RkGSrBXiyWtSgDV-5oVwxUCQCLQyU78SvaEVXcMg==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Elhan Webb, CFA<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XGMwtkCsnZtAweah9SPaQRc4WLBMFJK7_84mYi8pF-yiT3IDX9HOo01DlxAR4AQnbVXorSFAW9-cptfQpKHDRSmw9NzinPCI6AzCP3n4T0o=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>elhan.webb@rubiustx.com<\/strong><\/a><\/p>\n<p><strong>Media:\u00a0<\/strong><br \/>Marissa Hanify<br \/>Director, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_5g0zGIxeza7puyv_cwWyc7s7Vm8SYfBekWgg6UzALNv5FjX8M0xRPC0bOm6aRZs6StfY0ieiBQ_JYDLpLYT6IPKpD2rIaCsxzO2Hrhvj8_aZO9Cgkbdd39fl8sLTkxK\" rel=\"nofollow noopener\" target=\"_blank\"><strong>marissa.hanify@rubiustx.com<\/strong><\/a><\/p>\n<p>Dan Budwick<br \/>1AB <br \/>+1 (973) 271-6085<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3SLhHJF8osPjw9FW32WK8ApuM1Syb19UWk1S5_zlaSnIT8TSyEu5vSehFG2WwsqKKfAIkeZMs4OLgizyqEf21w==\" rel=\"nofollow noopener\" target=\"_blank\">dan@1abmedia.com<\/a><\/strong><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b76cb025-1464-4b5a-b22b-ebb20bbd2394\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc.\u00a0(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122 for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on\u00a0Monday, August 9, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary RED PLATFORM\u00ae was designed to genetically engineer and culture Red Cell Therapeutics\u2122 that are selective, potent and off-the-shelf allogeneic cellular therapies &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rubius Therapeutics to Announce Second Quarter 2021 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516432","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc.\u00a0(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122 for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on\u00a0Monday, August 9, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary RED PLATFORM\u00ae was designed to genetically engineer and culture Red Cell Therapeutics\u2122 that are selective, potent and off-the-shelf allogeneic cellular therapies &hellip; Continue reading &quot;Rubius Therapeutics to Announce Second Quarter 2021 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T12:33:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results\",\"datePublished\":\"2021-07-22T12:33:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/\"},\"wordCount\":246,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/\",\"name\":\"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\",\"datePublished\":\"2021-07-22T12:33:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk","og_description":"CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc.\u00a0(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122 for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on\u00a0Monday, August 9, 2021, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary RED PLATFORM\u00ae was designed to genetically engineer and culture Red Cell Therapeutics\u2122 that are selective, potent and off-the-shelf allogeneic cellular therapies &hellip; Continue reading \"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T12:33:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results","datePublished":"2021-07-22T12:33:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/"},"wordCount":246,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/","name":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=","datePublished":"2021-07-22T12:33:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDMyOCM0MzA3OTYzIzIxMjA3MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-announce-second-quarter-2021-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rubius Therapeutics to Announce Second Quarter 2021 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516432"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516432\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}